Breast Grand Round with A/Prof Shom Goel
Wednesday 4 September 12.30–1.30pm
Targeting the cell cycle machinery in breast cancer – new insights and opportunities
Acquired resistance to CDK4/6 inhibitors, commonly used in treating ER-positive/HER2-negative breast cancer, poses a significant clinical challenge. This resistance often develops through various mechanisms, including the loss of tumor suppressor proteins like RB1, amplification of the CDK4 or CDK6 genes, and activation of alternative signaling pathways such as PI3K/AKT/mTOR and MAPK/ERK. These changes enable cancer cells to bypass the G1/S checkpoint control, rendering CDK4/6 inhibitors ineffective.
Join us this Wednesday to learn more.
